ABIOMED (NASDAQ:ABMD) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.
Several other analysts have also recently weighed in on ABMD. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $213.00 price target for the company in a research note on Friday, December 29th. Piper Jaffray Companies reissued a “buy” rating on shares of ABIOMED in a research note on Thursday, January 4th. Jefferies Group increased their price target on shares of ABIOMED from $175.00 to $208.00 and gave the company a “buy” rating in a research note on Friday, September 29th. SunTrust Banks reissued a “buy” rating and issued a $195.00 price target on shares of ABIOMED in a research note on Wednesday, November 1st. Finally, BTIG Research reissued a “hold” rating on shares of ABIOMED in a research note on Sunday, October 29th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $194.67.
Shares of ABIOMED (ABMD) opened at $208.14 on Thursday. ABIOMED has a one year low of $103.53 and a one year high of $211.34. The stock has a market cap of $9,200.00, a PE ratio of 102.53, a P/E/G ratio of 2.67 and a beta of 0.15. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.20 and a current ratio of 5.84.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.16. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The company had revenue of $132.80 million during the quarter, compared to analysts’ expectations of $131.18 million. During the same quarter in the prior year, the company earned $0.20 EPS. ABIOMED’s revenue was up 28.9% compared to the same quarter last year. equities analysts expect that ABIOMED will post 2.41 earnings per share for the current year.
In other news, Director Dorothy E. Puhy sold 6,364 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $179.08, for a total value of $1,139,665.12. Following the transaction, the director now directly owns 39,532 shares in the company, valued at approximately $7,079,390.56. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Michael G. Howley sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the completion of the transaction, the vice president now owns 56,757 shares in the company, valued at $10,139,070.48. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Crow Point Partners LLC acquired a new position in shares of ABIOMED in the 4th quarter worth approximately $120,000. Atlantic Trust Group LLC acquired a new position in shares of ABIOMED in the 3rd quarter worth approximately $18,240,000. Sterling Capital Management LLC lifted its holdings in shares of ABIOMED by 2.2% in the 3rd quarter. Sterling Capital Management LLC now owns 13,139 shares of the medical equipment provider’s stock worth $2,215,000 after acquiring an additional 281 shares during the last quarter. California Public Employees Retirement System lifted its holdings in shares of ABIOMED by 1.7% in the 3rd quarter. California Public Employees Retirement System now owns 83,398 shares of the medical equipment provider’s stock worth $14,061,000 after acquiring an additional 1,398 shares during the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of ABIOMED by 46.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 2,903 shares of the medical equipment provider’s stock worth $489,000 after acquiring an additional 919 shares during the last quarter. Hedge funds and other institutional investors own 90.45% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “ABIOMED (ABMD) Upgraded at BidaskClub” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/01/11/abiomed-abmd-upgraded-at-bidaskclub.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.